Circulating tumor cells and biomarkers: Implications for personalized targeted treatments for metastatic breast cancer

Breast Journal

Volumn 16, Issue 3, 2010, Pages 327-330

  Reuben, James M ^a   Lee, Bang Ning ^a   Li, Changping ^a   Gao, Hui ^a   Broglio, Kristine R ^a   Valero, Vicente ^b   Jackson, Summer A ^b   Ueno, Naoto T ^b   Krishnamurthy, Savitri ^a   Hortobagyi, Gabriel N ^b   Cristofanilli, Massimo ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD24 ANTIGEN; CD44V ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NOTCH1 RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR;

BREAST CANCER; CANCER DIAGNOSIS; GENE EXPRESSION; HUMAN; LETTER; METASTASIS; METASTATIC BREAST CANCER; NONHUMAN; TUMOR CELL; TUMOR GROWTH; BREAST NEOPLASMS; CHEMISTRY; FEMALE; PATHOLOGY; PERSONALIZED MEDICINE; TUMOR EMBOLISM;

BREAST NEOPLASMS; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASTIC CELLS, CIRCULATING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 77953581988     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2010.00910.x     Document Type: Letter

References (11)

1. Swenerton KD, Legha SS, Smith T, et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 1979;39:1552-1562. (Pubitemid 9172673)
2. Hortobagyi GN, Smith TL, Legha SS, et al. Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1983;1:776-786.
3. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2197-2205.
4. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-791.
5. Budd GT, Cristofanilli M, Ellis MJ, et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006;12:6403-6409. (Pubitemid 44799711)
6. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-3988. (Pubitemid 36418143)
7. Balic M, Lin H, Young L, et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 2006;12:5615-5621.
8. Nunez-Villar MJ, Martinez-Arribas F, Pollan M, et al. Elevated mammaglobin (h-MAM) expression in breast cancer is associated with clinical and biological features defining a less aggressive tumour phenotype. Breast Cancer Res 2003;5:R65-R70.
9. Stylianou S, Clarke RB, Brennan K. Aberrant activation of notch signaling in human breast cancer. Cancer Res 2006;66:1517-1525.
10. Politi K, Feirt N, Kitajewski J. Notch in mammary gland development and breast cancer. Semin Cancer Biol 2004;14:341-347.
11. Parr C, Watkins G, Jiang WG. The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int J Mol Med 2004;14:779-786.